Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

✍ Scribed by Langley, R.G.; Papp, K.; Gottlieb, A.B.; Krueger, G.G.; Gordon, K. B.; Williams, D.; Valdes, J.; Setze, C.; Strober, B.

• Book ID: 121219702
• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 232 KB
• Category: Article
• ISSN: 0926-9959
• DOI: 10.1111/j.1468-3083.2012.04705.x